ArticleACS sensors2026
Oral Administration of a Bivalent Carbonic Anhydrase IX Near-Infrared Imaging Agent Detects Hypoxic Tumors in a Mouse Model.
Article in ACS sensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Early detection of breast cancer can significantly increase survival rates, and annual screening increases the chance of early detection. However, anatomical imaging methods, such as mammography, underperform in women with dense breast tissue, and alternatives such as ultrasound and magnetic resonance imaging can be more time- and cost-intensive. Molecular imaging methods have the potential to provide both spatial and molecular information, yielding advantages over traditional imaging. However, molecular imaging has previously been impractical for annual screening due to its high cost, risk of ionizing radiation, long acquisition time, and IV injection of contrast agents. Therefore, a cost-effective and lower-risk method is needed. This study reports the design of a bivalent near-infrared fluorophore sulfo-Cy5.5 carbonic anhydrase 9 (CAIX/CA9) targeting molecule (biAAZ-Cy5.5) for oral administration and fluorescent breast cancer screening. A challenge in developing orally delivered contrast agents is balancing sufficient oral bioavailability with efficient targeting and background clearance. Previous work from our group developed an integrin-targeting agent for oral delivery (α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.